Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II, double-blind, randomized, placebo-controlled study of the safety,
tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients
receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or
placebo) for a treatment period of 12-weeks.